Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.
NCT01618734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2012-06-13
Summary
TPO-r Switch is a retrospective study of the patients affected by Immune Thrombopenia (ITP) who received alternatively romiplostim and eltrombopag.
Conditions
- Immune Thrombocytopenia
- Thrombopoietin Receptor Agonist
Sponsors & Collaborators
-
Paris 12 Val de Marne University
collaborator OTHER -
Henri Mondor University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2012-06-30
- Completion
- 2012-06-30
More Related Trials
-
Indirect Comparison Between Eltrombopag & Romiplostim
NCT01236014 ·Status: COMPLETED
-
TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.
NCT02063763 ·Status: COMPLETED
-
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT04518475 ·Status: RECRUITING ·Phase: PHASE4
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
NCT04638829 ·Status: COMPLETED ·Phase: PHASE4
-
Immunomodulation With Romiplostim in Young Adults With ITP
NCT02760251 ·Status: COMPLETED ·Phase: PHASE4
-
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
NCT01143038 ·Status: COMPLETED ·Phase: PHASE2
-
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
NCT06137105 ·Status: NOT_YET_RECRUITING
-
Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
NCT01506414 ·Status: COMPLETED ·Phase: PHASE3
-
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
NCT01610180 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
NCT02279173 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP
NCT02338414 ·Status: UNKNOWN ·Phase: PHASE2
-
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT00907478 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
NCT07206823 ·Status: RECRUITING ·Phase: NA
-
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
NCT00902018 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
NCT03524612 ·Status: COMPLETED ·Phase: PHASE2
-
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
NCT04917679 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
NCT03771378 ·Status: UNKNOWN ·Phase: PHASE4
-
Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell
NCT01980030 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
NCT02402998 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
NCT02323178 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00908037 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
NCT02137681 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
NCT04200456 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of Eltrombopag at Escalated Doses
NCT01880047 ·Status: COMPLETED ·Phase: PHASE2